1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Saved in:
| Title: | 1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC). |
|---|---|
| Authors: | Godbert, Y.1 (AUTHOR), Cousin, S.2 (AUTHOR), Bellera, C.3 (AUTHOR), Guégan, J-P.4 (AUTHOR), Hadoux, J.5 (AUTHOR), Gomez-Roca, C.A.6 (AUTHOR), Cassier, P.7 (AUTHOR), Hescot, S.8 (AUTHOR), Vinches, M.9 (AUTHOR), Cantarel, C.10 (AUTHOR), Palussière, J.11 (AUTHOR), Kind, M.12 (AUTHOR), Soubeyran, I.13 (AUTHOR), Bessede, A.4 (AUTHOR), Italiano, A.14 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1120-S1120. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.2006 |
